The Use of a Zebrafish Germ Cell Tumor Mutant to Identify Putative Genetic Mutation Drivers in Human Testicular Germ Cells Tumors
The Use of a Zebrafish Germ Cell Tumor Mutant to Identify Putative Genetic Mutation Drivers in Human Testicular Germ Cells Tumors
批准号:
9355122
负责人:
KELLEE R SIEGFRIED
金额:
$9.26万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Adverse effectsAffectAftercareAgeAge-YearsAnimal ModelAnimalsAreaBasic ScienceBostonCancer CenterCancer Research ProjectCandidate Disease GeneClassificationCollaborationsCollectionDNA Sequence AlterationDana-Farber Cancer InstituteDataDevelopmentDiagnostic testsDiseaseFacultyFishesGenesGeneticGenomicsGerm CellsGerm cell tumorGoalsHumanIncidenceKnowledgeLeadLesionLifeMalignant NeoplasmsMassachusettsModelingMolecularMutateMutationNamesOncologistPathologistPathway interactionsPatientsPhenotypePilot ProjectsPredispositionPrimary NeoplasmQuality of lifeResearchResearch PersonnelResearch SupportResistanceRodent ModelSample SizeSamplingSeminomaSideTechniquesTechnologyTesticular Germ Cell TumorTestingTherapeutic InterventionTranslatingTumor Cell LineTumor stageTumor-DerivedTumorigenicityUnderrepresented StudentsUniversitiesVariantWorkZebrafishactionable mutationanticancer researchcancer health disparitycancer typecareer developmentcost effectivediagnostic biomarkerexomeexome sequencingexperiencegene discoverygenetic analysisgenetic predictorsgenetic variantgenome sequencinggenomic datahistological studieshuman datahuman diseaseimprovedmodel buildingmutantnovelprogramsrare varianttargeted treatmenttumortumorigenesistumorigenicunderrepresented minority studentwhole genomeyoung man
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Summary: Testicular Germ Cell Tumors (TGCTs) are the most common type of cancer affecting younger men
between the ages of 20 and 40 years old. TGCTs typically respond well to current treatments, yet about 5% of
cases are resistant. Furthermore, current treatments can have many adverse side affects that extend later in
life warranting the need for improved, more targeted therapies. However, the genetic and molecular causes of
TGCTs are largely unknown. To develop improved treatments for this disease requires a better understanding
of the molecular underpinnings of TGCT formation. The aims of the project are to uncover mutations that drive
TGCT tumorigenesis and/or increase susceptibility, and identify putative causative variants in human TGCTs
through two main approaches: 1) develop an animal model with a high incidence of TGCTs, and 2) genome
sequencing of tumor samples derived from patients. TGCTs consist of several subtypes, only one of which has
an available mammalian model. Furthermore, TGCT cell lines are notoriously difficult to derive and are
therefore largely unavailable. The zebrafish is an excellent animal model for many human diseases, including
cancer. Strikingly, two zebrafish mutant lines have been identified that give rise to seminoma-type TGCT,
which is the most common TGCT. Studies of these existing mutants identified mutated or misregulated genes
in human TGCTs. We identified a novel zebrafish mutant line with a high incidence of TGCTs, named zgt
(zebrafish germ cell tumor). This mutant is distinct from known zebrafish TGCT mutants and thus provides
novel inroads to discovering molecular mechanisms underlying TGCT formation. To test for drivers of TGCTs
in humans, this pilot proposes a genomic sequencing approach of patient samples with the goal of discovering
mutations that arise during TGCT formation and thus may drive tumorigenesis. To facilitate identification of
rare alleles, the project will use the knowledge gained from studies of our zebrafish model to guide targeted
searches for mutations in human patient samples. This approach will facilitate the identification of mutations
that may drive tumorigenesis, even with a limited number of primary tumor samples. Through this work, this
pilot project will establish a new animal model for TGCT studies that will be used to uncover genetic and
mechanistic causes of tumor formation. The project will translate the knowledge gained from the animal model
through comparisons with genomic analysis attained from tumors derived from human patients, which will
facilitate the identification of potential areas for therapeutic intervention. This project directly relates to the
goals of the U54 Partnership as it supports collaborative research between oncologists and pathologists at
DF/HCC and a basic science research group at UMass Boston. This collaboration is essential in establishing
the project's translational model and building the cancer research program at UMass Boston. Furthermore, this
project will provide opportunities for underrepresented minority (URM) students to engage in cancer research,
and support career development of early stage investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Spermatogonial stem cell regulation and maintenance of male fertility
-
批准号:10360087
-
项目类别:
-
资助金额:$45.75万
-
财政年份:2022
-
负责人:KELLEE R SIEGFRIED
-
依托单位:
The Use of a Zebrafish Germ Cell Tumor Mutant to Identify Putative Genetic Mutation Drivers in Human Testicular Germ Cells Tumors
-
批准号:9211685
-
项目类别:
-
资助金额:$9.61万
-
财政年份:--
-
负责人:KELLEE R SIEGFRIED
-
依托单位:
海外基金